drugset
drugset / Trial / NCT02673476

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

NCT02673476 ↗

Phase 2 Completed 9 enrolled Alios Biopharma Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is being to see how effective and safe ALS-008176 is in treating adults in the hospital with a Respiratory Syncytial Virus-Related Illness.

Timeline

Start
2016-02-29
Primary completion
2016-10-31
Completion
2016-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumicitabine Small molecule — Oral

Indications

respiratory syncytial virus infectious disease